ADMP News and Press, Adamis Pharmaceuticals Corporation From 05/18/22

David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceuti...

Adamis Pharma (NASDAQ:ADMP -9.4%) posted better-than expected Q1 revenue on Monday after markets closed. Quarterly revenue fell 14% Y/Y to $1.2M, but beat analysts estimate by $1.1M. Revenues consisted mostly of about  $1.1M of sales from opioid overdose treatment, Zi...

Adamis Pharmaceuticals Corporation (ADMP) Q1 2022 Earnings Conference Call May 16, 2022 17:00 ET Corporate Participants Robert Uhl - ICR Westwicke Dennis Carlo - President and Chief Executive Officer David Benedicto - Chief Financial Officer Ron Moss - Chief Medical Officer David Marguglio - ...

Adamis Pharmaceuticals press release (NASDAQ:ADMP): Q1 net loss from discontinued operations was approximately $0.17M vs. loss of $1.5M last year. Revenue of $1.2M (-14.3% Y/Y) beats by $1.1M. Cash and cash equivalents at March 31, 2022, totaled approximately $17.8 million. For further deta...

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the quar...

SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor ...

Adamis Pharmaceuticals has two intramuscular injection rescue products approved by the FDA, SYMJEPI, and ZIMHI. In addition, the company's COVID-19 candidate, TEMPOL, has shown incredible promise thus far. Despite hitting their objectives and making significant progress, these efforts...

Adamis Pharmaceuticals Corporation (ADMP) Q4 2021 Earnings Conference Call March 31, 2022 5:00 PM ET Company Participants Robert Uhl - ICR Westwicke Dr. Dennis Carlo - President, CEO and Director David Benedicto - CFO Dr. Ron Moss - Chief Medical Officer David Marguglio - Senior VP, Chief Bus...

Adamis Pharmaceuticals press release (NASDAQ:ADMP): Q4 Revenue of $2.2M (-21.4% Y/Y) beats by $0.9M. Cash and equivalents as of December 31, 2021, totaled approximately $23.2 million. Net loss from discontinued operations for the twelve months ended December 31, 2021, and 2020 was $11.2 milli...

SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the ye...